Search
rsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnrsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.
Methyclothiazide
go.drugbank.com/drugs/DB00232ApprovedWithdrawnA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigationalLecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology … [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … [A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy.
Imelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigational[L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922] … Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.
Synonyms: L-Methyl Dopa, α-methyl-L-dopaCategories: Aromatic L-amino Acid Decarboxylase InhibitorsEvinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalEvinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH. … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalHowever, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect. … Miglustat was first developed as an anti-HIV agent in the 1990s.
Synonyms: N-(n-Butyl)deoxynojirimycin, N-ButylmoranolineDiphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalA meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Mixtures: PHARMANIAGA DIPHENOXYLATE A TABLETPhenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigationalPhenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. … [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Categories: Monoamine Oxidase A Substrates